Endocrine Abstracts

Ipilimumab, a monoclonal antibody against CTLA-4, is licenced for the treatment of metastatic melanoma (dose of 3 mg/kg for four cycles intravenously). It can cause immune-related adverse reactions (IRAEs) in multiple organs, with hypophysitis the most common endocrine IRAE. We carried out a retrospective analysis of 171 ipilimumab-treated patients in one centre for endocrinopathies.Results: Nine cases (six female, mean age 64 years, range 42–76) of...